Boston  ||| S:0 E:7 ||| NNP
Scientific  ||| S:7 E:18 ||| NNP
Lotus  ||| S:18 E:24 ||| NNP
valve  ||| S:24 E:30 ||| NN
As  ||| S:30 E:33 ||| IN
a  ||| S:33 E:35 ||| DT
result  ||| S:35 E:42 ||| NN
of  ||| S:42 E:45 ||| IN
recent  ||| S:45 E:52 ||| JJ
randomised  ||| S:52 E:63 ||| NNS
controlled  ||| S:63 E:74 ||| VBN
trials  ||| S:74 E:81 ||| NNS
and  ||| S:81 E:85 ||| CC
registry  ||| S:85 E:94 ||| JJ
observations ||| S:94 E:106 ||| NNS
,  ||| S:106 E:108 ||| ,
transcatheter  ||| S:108 E:122 ||| FW
aortic  ||| S:122 E:129 ||| FW
valve  ||| S:129 E:135 ||| FW
replacement  ||| S:135 E:147 ||| FW
( ||| S:147 E:148 ||| -LRB-
TAVR ||| S:148 E:152 ||| NNP
)  ||| S:152 E:154 ||| -RRB-
enjoys  ||| S:154 E:161 ||| VBZ
growing  ||| S:161 E:169 ||| VBG
appeal  ||| S:169 E:176 ||| NN
for  ||| S:176 E:180 ||| IN
the  ||| S:180 E:184 ||| DT
treatment  ||| S:184 E:194 ||| NN
of  ||| S:194 E:197 ||| IN
patients  ||| S:197 E:206 ||| NNS
at  ||| S:206 E:209 ||| IN
high  ||| S:209 E:214 ||| JJ
or  ||| S:214 E:217 ||| CC
extreme  ||| S:217 E:225 ||| JJ
risk  ||| S:225 E:230 ||| NN
from  ||| S:230 E:235 ||| IN
surgical  ||| S:235 E:244 ||| JJ
aortic  ||| S:244 E:251 ||| JJ
valve  ||| S:251 E:257 ||| JJ
replacement ||| S:257 E:268 ||| NN
.  ||| S:268 E:270 ||| .
However ||| S:270 E:277 ||| RB
,  ||| S:277 E:279 ||| ,
the  ||| S:279 E:283 ||| DT
current  ||| S:283 E:291 ||| JJ
technologies  ||| S:291 E:304 ||| NNS
and  ||| S:304 E:308 ||| CC
techniques  ||| S:308 E:319 ||| NNS
have  ||| S:319 E:324 ||| VBP
important  ||| S:324 E:334 ||| JJ
limitations ||| S:334 E:345 ||| NNS
,  ||| S:345 E:347 ||| ,
including  ||| S:347 E:357 ||| VBG
risk  ||| S:357 E:362 ||| NN
of  ||| S:362 E:365 ||| IN
stroke ||| S:365 E:371 ||| NN
,  ||| S:371 E:373 ||| ,
vascular  ||| S:373 E:382 ||| JJ
complications  ||| S:382 E:396 ||| NNS
and  ||| S:396 E:400 ||| CC
paravalvular  ||| S:400 E:413 ||| JJ
aortic  ||| S:413 E:420 ||| JJ
regurgitation ||| S:420 E:433 ||| NN
,  ||| S:433 E:435 ||| ,
which  ||| S:435 E:441 ||| WDT
may  ||| S:441 E:445 ||| MD
in  ||| S:445 E:448 ||| RB
turn  ||| S:448 E:453 ||| VB
influence  ||| S:453 E:463 ||| NN
survival ||| S:463 E:471 ||| NN
.  ||| S:471 E:473 ||| .
While  ||| S:473 E:479 ||| IN
careful  ||| S:479 E:487 ||| JJ
patient  ||| S:487 E:495 ||| NN
selection  ||| S:495 E:505 ||| NN
and  ||| S:505 E:509 ||| CC
screening  ||| S:509 E:519 ||| NN
may  ||| S:519 E:523 ||| MD
improve  ||| S:523 E:531 ||| VB
outcomes ||| S:531 E:539 ||| NNS
,  ||| S:539 E:541 ||| ,
new  ||| S:541 E:545 ||| JJ
valve  ||| S:545 E:551 ||| NN
designs  ||| S:551 E:559 ||| NNS
and  ||| S:559 E:563 ||| CC
iterations  ||| S:563 E:574 ||| NNS
are  ||| S:574 E:578 ||| VBP
required ||| S:578 E:586 ||| VBN
.  ||| S:586 E:588 ||| .
The  ||| S:588 E:592 ||| DT
Lotus  ||| S:592 E:598 ||| NNP
aortic  ||| S:598 E:605 ||| VBD
valve  ||| S:605 E:611 ||| JJ
replacement  ||| S:611 E:623 ||| NN
system  ||| S:623 E:630 ||| NN
is  ||| S:630 E:633 ||| VBZ
a  ||| S:633 E:635 ||| DT
new  ||| S:635 E:639 ||| JJ
fully  ||| S:639 E:645 ||| RB
repositionable  ||| S:645 E:660 ||| JJ
device  ||| S:660 E:667 ||| NN
designed  ||| S:667 E:676 ||| VBN
to  ||| S:676 E:679 ||| TO
facilitate  ||| S:679 E:690 ||| VB
more  ||| S:690 E:695 ||| RBR
precise  ||| S:695 E:703 ||| JJ
delivery  ||| S:703 E:712 ||| NN
and  ||| S:712 E:716 ||| CC
minimise  ||| S:716 E:725 ||| JJ
paravalvular  ||| S:725 E:738 ||| JJ
regurgitation ||| S:738 E:751 ||| NN
.  ||| S:751 E:753 ||| .
The  ||| S:753 E:757 ||| DT
safety  ||| S:757 E:764 ||| NN
and  ||| S:764 E:768 ||| CC
efficacy  ||| S:768 E:777 ||| NN
of  ||| S:777 E:780 ||| IN
the  ||| S:780 E:784 ||| DT
Lotus  ||| S:784 E:790 ||| NNP
valve  ||| S:790 E:796 ||| NNS
are  ||| S:796 E:800 ||| VBP
being  ||| S:800 E:806 ||| VBG
studied  ||| S:806 E:814 ||| VBN
systematically  ||| S:814 E:829 ||| RB
in  ||| S:829 E:832 ||| IN
the  ||| S:832 E:836 ||| DT
REPRISE  ||| S:836 E:844 ||| NNP
clinical  ||| S:844 E:853 ||| JJ
trial  ||| S:853 E:859 ||| NN
programme ||| S:859 E:868 ||| NN
.  ||| S:868 E:870 ||| .
